Asciminib in Relapsed Chronic Myeloid Leukemia
To the Editor: Hughes et al. (Dec. 12 issue) 1 report antileukemic activity of asciminib in pretreated patients with chronic myeloid leukemia (CML). A major molecular response was achieved or maintained by 12 months in 28% of the patients (5 of 18) with a T315I mutation at baseline. One of these 5 p...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2020-04, Vol.382 (14), p.1378-1379 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1379 |
|---|---|
| container_issue | 14 |
| container_start_page | 1378 |
| container_title | The New England journal of medicine |
| container_volume | 382 |
| creator | Sahin, Ilyas Reagan, John L Mauro, Michael J Hughes, Timothy P |
| description | To the Editor:
Hughes et al. (Dec. 12 issue)
1
report antileukemic activity of asciminib in pretreated patients with chronic myeloid leukemia (CML). A major molecular response was achieved or maintained by 12 months in 28% of the patients (5 of 18) with a T315I mutation at baseline. One of these 5 patients in whom a major molecular response was achieved or maintained by 12 months was 1 of the 5 patients in the study who had ponatinib resistance and a T315I mutation. Although ponatinib is the only tyrosine kinase inhibitor approved by the Food and Drug Administration that has shown . . . |
| doi_str_mv | 10.1056/NEJMc2000116 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2386279931</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2386279931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c278t-654a5babca6a3ca9686b8db35ee6d320f908a52580fe124e6be5b8e5d15eb7f93</originalsourceid><addsrcrecordid>eNpt0EtLw0AUhuFBFK3VnWsJ6MKFqXPJXLIspd5oFUTXw8zkBKdmkpppFv33prSKiKuzefg4vAidETwimIubp-nj3FGMMSFiDw0IZyzNMiz20QBjqtJM5uwIHce4wBuU5YfoiFGaUSb5AI3G0fnga28TXycvUJllhCKZvLdN7V0yX0PV-CKZQfcBwZsTdFCaKsLp7g7R2-30dXKfzp7vHibjWeqoVKtU8Mxwa6wzwjBncqGEVYVlHEAUjOIyx8pwyhUugdAMhAVuFfCCcLCyzNkQXW13l23z2UFc6eCjg6oyNTRd1JQpQWWeM9LTiz900XRt3X-3UZwJJZXs1fVWubaJsYVSL1sfTLvWBOtNR_27Y8_Pd6OdDVD84O9wPbjcghCirmER_t_5AmOSdhk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2385368787</pqid></control><display><type>article</type><title>Asciminib in Relapsed Chronic Myeloid Leukemia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Sahin, Ilyas ; Reagan, John L ; Mauro, Michael J ; Hughes, Timothy P</creator><creatorcontrib>Sahin, Ilyas ; Reagan, John L ; Mauro, Michael J ; Hughes, Timothy P</creatorcontrib><description>To the Editor:
Hughes et al. (Dec. 12 issue)
1
report antileukemic activity of asciminib in pretreated patients with chronic myeloid leukemia (CML). A major molecular response was achieved or maintained by 12 months in 28% of the patients (5 of 18) with a T315I mutation at baseline. One of these 5 patients in whom a major molecular response was achieved or maintained by 12 months was 1 of the 5 patients in the study who had ponatinib resistance and a T315I mutation. Although ponatinib is the only tyrosine kinase inhibitor approved by the Food and Drug Administration that has shown . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc2000116</identifier><identifier>PMID: 32242375</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Chronic myeloid leukemia ; Humans ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Mutation ; Myeloid leukemia ; Niacinamide - analogs & derivatives ; Protein Kinase Inhibitors ; Protein-tyrosine kinase ; Pyrazoles</subject><ispartof>The New England journal of medicine, 2020-04, Vol.382 (14), p.1378-1379</ispartof><rights>Copyright © 2020 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c278t-654a5babca6a3ca9686b8db35ee6d320f908a52580fe124e6be5b8e5d15eb7f93</citedby><cites>FETCH-LOGICAL-c278t-654a5babca6a3ca9686b8db35ee6d320f908a52580fe124e6be5b8e5d15eb7f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc2000116$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2385368787?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32242375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sahin, Ilyas</creatorcontrib><creatorcontrib>Reagan, John L</creatorcontrib><creatorcontrib>Mauro, Michael J</creatorcontrib><creatorcontrib>Hughes, Timothy P</creatorcontrib><title>Asciminib in Relapsed Chronic Myeloid Leukemia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Hughes et al. (Dec. 12 issue)
1
report antileukemic activity of asciminib in pretreated patients with chronic myeloid leukemia (CML). A major molecular response was achieved or maintained by 12 months in 28% of the patients (5 of 18) with a T315I mutation at baseline. One of these 5 patients in whom a major molecular response was achieved or maintained by 12 months was 1 of the 5 patients in the study who had ponatinib resistance and a T315I mutation. Although ponatinib is the only tyrosine kinase inhibitor approved by the Food and Drug Administration that has shown . . .</description><subject>Chronic myeloid leukemia</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</subject><subject>Mutation</subject><subject>Myeloid leukemia</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Protein Kinase Inhibitors</subject><subject>Protein-tyrosine kinase</subject><subject>Pyrazoles</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0EtLw0AUhuFBFK3VnWsJ6MKFqXPJXLIspd5oFUTXw8zkBKdmkpppFv33prSKiKuzefg4vAidETwimIubp-nj3FGMMSFiDw0IZyzNMiz20QBjqtJM5uwIHce4wBuU5YfoiFGaUSb5AI3G0fnga28TXycvUJllhCKZvLdN7V0yX0PV-CKZQfcBwZsTdFCaKsLp7g7R2-30dXKfzp7vHibjWeqoVKtU8Mxwa6wzwjBncqGEVYVlHEAUjOIyx8pwyhUugdAMhAVuFfCCcLCyzNkQXW13l23z2UFc6eCjg6oyNTRd1JQpQWWeM9LTiz900XRt3X-3UZwJJZXs1fVWubaJsYVSL1sfTLvWBOtNR_27Y8_Pd6OdDVD84O9wPbjcghCirmER_t_5AmOSdhk</recordid><startdate>20200402</startdate><enddate>20200402</enddate><creator>Sahin, Ilyas</creator><creator>Reagan, John L</creator><creator>Mauro, Michael J</creator><creator>Hughes, Timothy P</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20200402</creationdate><title>Asciminib in Relapsed Chronic Myeloid Leukemia</title><author>Sahin, Ilyas ; Reagan, John L ; Mauro, Michael J ; Hughes, Timothy P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c278t-654a5babca6a3ca9686b8db35ee6d320f908a52580fe124e6be5b8e5d15eb7f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chronic myeloid leukemia</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</topic><topic>Mutation</topic><topic>Myeloid leukemia</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Protein Kinase Inhibitors</topic><topic>Protein-tyrosine kinase</topic><topic>Pyrazoles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahin, Ilyas</creatorcontrib><creatorcontrib>Reagan, John L</creatorcontrib><creatorcontrib>Mauro, Michael J</creatorcontrib><creatorcontrib>Hughes, Timothy P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahin, Ilyas</au><au>Reagan, John L</au><au>Mauro, Michael J</au><au>Hughes, Timothy P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Asciminib in Relapsed Chronic Myeloid Leukemia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2020-04-02</date><risdate>2020</risdate><volume>382</volume><issue>14</issue><spage>1378</spage><epage>1379</epage><pages>1378-1379</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Hughes et al. (Dec. 12 issue)
1
report antileukemic activity of asciminib in pretreated patients with chronic myeloid leukemia (CML). A major molecular response was achieved or maintained by 12 months in 28% of the patients (5 of 18) with a T315I mutation at baseline. One of these 5 patients in whom a major molecular response was achieved or maintained by 12 months was 1 of the 5 patients in the study who had ponatinib resistance and a T315I mutation. Although ponatinib is the only tyrosine kinase inhibitor approved by the Food and Drug Administration that has shown . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>32242375</pmid><doi>10.1056/NEJMc2000116</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2020-04, Vol.382 (14), p.1378-1379 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2386279931 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Chronic myeloid leukemia Humans Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Mutation Myeloid leukemia Niacinamide - analogs & derivatives Protein Kinase Inhibitors Protein-tyrosine kinase Pyrazoles |
| title | Asciminib in Relapsed Chronic Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T18%3A18%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Asciminib%20in%20Relapsed%20Chronic%20Myeloid%20Leukemia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Sahin,%20Ilyas&rft.date=2020-04-02&rft.volume=382&rft.issue=14&rft.spage=1378&rft.epage=1379&rft.pages=1378-1379&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc2000116&rft_dat=%3Cproquest_cross%3E2386279931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2385368787&rft_id=info:pmid/32242375&rfr_iscdi=true |